No Data
No Data
FibroBiologics 1Q Loss/Shr 27c >FBLG
FibroBiologics 1Q Loss/Shr 27c >FBLG
FibroBiologics | 10-Q: Quarterly report
FibroBiologics to Present at the BIO International Convention 2024
HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of
FibroBiologics Files to Sell 1.8M Units
FibroBiologics, Charles River Laboratories Sign Letter Of Intent Allowing For Transfer, Testing And Validation Of Technology
This agreement comes ahead of entering into an anticipated master services agreement for the development and manufacture of FibroBiologics' master cell bank, working cell bank, and fibroblast-based sp
FibroBiologics Plans to Collaborate With Charles River to Manufacture Fibroblast-based Spheroids
HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics") and Charles River Laboratories ("Charles River"), a highly respected, global provider of drug discovery,
No Data